← Back to Search

Computed Tomography Perfusion Imaging for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Led By Maximilian Diehn

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 4 months post-sabr

Awards & highlights

Study Summary

This trial looks at whether CT perfusion imaging can predict how well patients with non-small cell lung cancer or metastases will respond to stereotactic ablative radiation therapy.

Eligible Conditions

Non-Small Cell Lung Cancer
Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 months post-sabr

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 months post-sabr

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 months post-sabr for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants able to complete perfusion scan acquisition at the time of treatment-planning

Number of participants able to complete perfusion scan acquisition in follow-up up to 4 months after SABR

Number of participants able to complete perfusion scan acquisition within 48 hours of SABR

Secondary outcome measures

The calculated variance of blood flow such that measurable changes can be identified in future studies

The calculated variance of blood volume such that measurable changes can be identified in future studies

The calculated variance of mean transit time such that measurable changes can be identified in future studies

+1 more

Side effects data

From 2018 Phase 2 trial • 22 Patients • NCT02101918

77%

Hypertension

68%

Headache

45%

Mucositis oral

41%

Hoarseness

32%

Proteinuria

27%

Fatigue

23%

Constipation

23%

Nausea

23%

Abdominal pain

23%

Vomiting

18%

Alanine aminotransferase increased

18%

Diarrhea

18%

Arthralgia

14%

Neutrophil count decreased

14%

Creatinine increased

14%

Anorexia

14%

Pain

14%

Palmar-plantar erythrodysesthesia syndrome

14%

Epistaxis

14%

Weight loss

14%

Aspartate aminotransferase increased

14%

Platelet count decreased

14%

Anemia

Sinusitis

Dehydration

Upper gastrointestinal hemorrhage

cholecystitis

Hemorrhage Upper GI

Pain Abdominal

100%

80%

60%

40%

20%

Study treatment Arm

Aflibercept 6 mg /kg IV

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (CT perfusion imaging)Experimental Treatment3 Interventions

Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CAPP-Seq

2016

Completed Phase 1

~20

Isovue-200

2016

Completed Phase 1

~20

Computed Tomography Perfusion Imaging

2016

Completed Phase 2

~90

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,576 Total Patients Enrolled

Maximilian DiehnPrincipal InvestigatorStanford University

2 Previous Clinical Trials

2,028 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the safety profile of Computed Tomography Perfusion Imaging for individuals?

"Our assessment of Computed Tomography Perfusion Imaging's safety is a 1, due to the fact that this trial is in its preliminary stages and there exists limited evidence regarding efficacy."

Answered by AI

For what medical conditions is Computed Tomography Perfusion Imaging routinely utilized?

"CT Perfusion Imaging is a valid technique for observing urography, computerized tomography, and myelography."

Answered by AI

Are there any vacancies available for patients to join this medical trial?

"This particular clinical trial, which was first posted on January 19th 2016 and last updated May 31st 2022 is no longer searching for participants. Fortunately, there are 4286 other active studies recruiting patients at this time."

Answered by AI

What is the estimated population size involved in this research?

"Sadly, participant recruitment for this trial has concluded. It began on January 19th 2016 and was last updated on May 31st 2022. If other studies interest you, there are presently 4282 experiments investigating lung health and 4 trials that utilise Computed Tomography Perfusion Imaging in search of volunteers."

Answered by AI

What other investigations have been conducted with regard to Computed Tomography Perfusion Imaging?

"Currently, 4 clinical investigations pertaining to Computed Tomography Perfusion Imaging are ongoing with none in Phase 3. Patients residing near Omaha, Nebraska have access to 8 different locations offering trials for this imaging technique."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

2016. "CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02693080.